Core Insights - Mersana Therapeutics is advancing its clinical-stage biopharmaceutical pipeline, particularly focusing on the development of antibody-drug conjugates (ADCs) for cancer treatment, with a significant emphasis on addressing high unmet medical needs in oncology [1][17] Clinical Development - The company is developing Emi-Le (emiltatug ledadotin), a B7-H4-directed Dolasynthen ADC, and has reported promising preliminary clinical data at the ESMO Breast Cancer 2025 conference, indicating an increase in the objective response rate (ORR) to 31% among evaluable patients with B7-H4 high tumors [2][4][6] - The ongoing Phase 1 clinical trial of Emi-Le is focused on triple-negative breast cancer (TNBC) patients who have received one to four prior lines of therapy, with significant progress in patient enrollment for both dose expansion cohorts [9][10] - The company plans to report initial clinical data from the expansion portion of the Phase 1 trial in the second half of 2025 [6][10] Financial Performance - As of March 31, 2025, Mersana reported cash and cash equivalents of $102.3 million, with net cash used in operating activities for the first quarter amounting to $29.3 million [14] - Collaboration revenue for the first quarter of 2025 was $2.8 million, a decrease from $9.2 million in the same period in 2024, primarily due to reduced revenue from collaborations with Johnson & Johnson and Merck KGaA [14] - The net loss for the first quarter of 2025 was $24.1 million, or $0.19 per share, compared to a net loss of $19.3 million, or $0.16 per share, for the same period in 2024 [19][24] Collaborations and Partnerships - Mersana continues to support collaborations with Johnson & Johnson and Merck KGaA, focusing on research related to its Dolasynthen and Immunosynthen ADC platforms [13][17] - GSK plc holds an exclusive global license option to co-develop and commercialize Mersana's lead Immunosynthen ADC candidate, XMT-2056 [12]

Group 1 - X Financial will release its unaudited financial results for Q1 2025 on May 20, 2025, before U.S. market opens [1] - The earnings conference call is scheduled for 7:30 AM U.S. Eastern Time on the same day [1] - Dial-in details for the conference call have been provided for various regions, including the U.S., Hong Kong, and Mainland China [2] Group 2 - X Financial is a leading online personal finance company in China, focusing on connecting borrowers with institutional funding partners [3] - The company utilizes proprietary big data-driven technology to establish strategic partnerships with financial institutions [3] - X Financial has a robust risk assessment and control system to facilitate loans to prime borrowers [3]

Core Viewpoint - Futu Holdings Limited is set to announce its financial results for the first quarter of 2025 on May 29, 2025, before U.S. markets open, with a conference call scheduled for the same day [1]. Group 1: Financial Results Announcement - Futu will report its financial results for Q1 2025 on May 29, 2025 [1]. - The earnings conference call will take place at 7:30 AM U.S. Eastern Time [1]. Group 2: Conference Call Registration - Participants must pre-register for the conference call via a provided link [2]. - Confirmation emails will include dial-in numbers and personal PINs for access [3]. Group 3: Company Overview - Futu Holdings Limited is a tech-driven online brokerage and wealth management platform [4]. - The company offers a range of digital financial services through its platforms, including trade execution, margin financing, and wealth management [4]. - Futu integrates social media tools to enhance user connectivity and engagement [4].

Core Viewpoint - Gaotu Techedu Inc. reported strong financial results for the first quarter of 2025, with significant year-over-year growth in revenues and profitability, driven by enhanced operational efficiency and strategic investments in AI-powered educational solutions [1][5][10]. Financial Performance - Net revenues increased by 57.7% to RMB1,493.0 million from RMB946.9 million in Q1 2024 [3][10]. - Gross billings rose by 21.8% to RMB888.7 million from RMB729.4 million in the same period [3][10]. - Income from operations was RMB34.8 million, a turnaround from a loss of RMB77.7 million in Q1 2024 [3][14]. - Net income reached RMB124.0 million, compared to a net loss of RMB12.3 million in the prior year [3][19]. - Non-GAAP net income surged by 4,419.2% to RMB137.3 million from RMB3.0 million in Q1 2024 [3][19]. Operational Highlights - The company achieved a net income margin of 9.2% and an operating margin increase of 10.5 percentage points year-over-year [5][8]. - Deferred revenue balance grew by 44.0% to over RMB1.4 billion, indicating strong future revenue potential [8]. - The company allocated RMB136 million for share repurchases, with a total of approximately RMB460 million under the current buyback plan [6][9]. Strategic Initiatives - Gaotu is focusing on creating a technology-empowered value loop in education by integrating AI into its products and services, enhancing user experience and learning outcomes [7][9]. - The company plans to continue investing in product quality and expanding its user base to meet evolving customer needs [9]. Future Outlook - For Q2 2025, total net revenues are expected to be between RMB1,298 million and RMB1,318 million, reflecting a year-over-year increase of 28.5% to 30.5% [26].

Core Insights - Nexus Industrial REIT has successfully transitioned to a pure-play industrial REIT, with industrial assets now contributing over 99% of its net operating income (NOI) [2][8] - The company reported a 8.6% increase in NOI year-over-year, reaching CAD 32.1 million, driven by acquisitions and growth in industrial Same Property NOI, which increased by 6.6% [8][16] - The REIT anticipates continued growth, with two significant development projects expected to add approximately CAD 6.6 million in annual stabilized NOI upon completion [2][18] Financial Performance - For Q1 2025, property revenues increased to CAD 44.8 million from CAD 41.6 million in Q1 2024 [10] - Net income for the quarter was CAD 33.2 million, down from CAD 43.7 million in the previous year, primarily due to fair value adjustments [10][31] - Normalized FFO per unit increased to CAD 0.187, up CAD 0.022 from the previous year, while Normalized AFFO per unit rose to CAD 0.154, an increase of CAD 0.019 [10][32] Portfolio and Occupancy - The REIT's total portfolio consists of 90 investment properties, with a fair value of CAD 2.47 billion, and a gross leasable area of approximately 11.7 million square feet [13][27] - The industrial occupancy rate increased to 97% from 96% in 2024, indicating strong demand for industrial space [8][13] - The weighted average lease term for the industrial portfolio is 6.8 years, reflecting stability in tenant relationships [13] Development Projects - The REIT is advancing construction on a 325,000 sq. ft. expansion project in St. Thomas, ON, and a 115,000 sq. ft. small-bay industrial complex in Calgary, AB, both expected to be completed in Q3 2025 [8][23] - The expansion project is projected to yield a contractual going-in yield of 9.0% on total development costs of CAD 54.9 million, while the Calgary project is expected to yield approximately 11% on CAD 15.4 million [23] Strategic Initiatives - The company sold 15 legacy retail properties and one office property for total proceeds of CAD 50.9 million, using the proceeds to reduce debt and fund development projects [2][8] - The REIT has renewed over 80% of its expiring gross leasable area (GLA), contributing an additional CAD 2.6 million to NOI in 2025 [4][8]

Loan Interest Revenue up 45% and Recurring Free Cash Flow up 104% year over year TORONTO, ON, May 14, 2025 (GLOBE NEWSWIRE) -- Flow Capital Corp. (TSXV:FW), a leading provider of flexible growth capital and alternative debt solutions, announces its unaudited financial and operating results for the for the three-months ended March 31, 2025. Q1 2025 Performance Highlights 45% increase in Loan Interest Revenue to $2.9 million year over year.104% increase in Recurring Free Cash Flow to $847,111 year over year. ...

Core Viewpoint - Catheter Precision, Inc. reported significant operational updates and financial results for Q1 2025, highlighting growth in sales and strategic acquisitions aimed at enhancing its product pipeline in the electrophysiology market [1][6]. Commercial Endeavors - Approximately 50 hospitals are evaluating Catheter Precision's devices, VIVO and LockeT, indicating a strong sales pipeline [3]. - The company acquired Cardionomics, Inc.'s assets, including a new therapy for acute decompensated heart failure, which affects over 1 million Americans annually [3]. - The acquisition of PeriKard, LLC aims to develop a kit for easier access to the pericardial space, improving existing methods [3]. - New and repeat customers placed orders during the March quarter, reflecting growing market acceptance [3]. Clinical Studies and Presentations - Four abstracts were accepted for presentation at the Heart Rhythm Society Symposia, showcasing the efficacy of VIVO and LockeT in various clinical scenarios [3]. - A study involving 125 centers in Europe showed VIVO's accuracy over 94% and long-term procedural success exceeding 83% [3]. - LockeT demonstrated safety and effectiveness in a study of 139 patients, improving hemostasis in large-bore access procedures [3]. - VIVO's accuracy in scar-dependent VT was validated, predicting exit site locations with 89% accuracy [3]. Financial Highlights - Total assets as of March 31, 2025, were $24.8 million, with total shareholders' equity at $7.9 million [12]. - Sales revenues for Q1 2025 increased by 74% to approximately $143 thousand compared to $82 thousand in Q1 2024 [12]. - The net loss for the quarter was approximately $4.0 million, with $1.2 million attributed to non-cash charges [12]. - The cash position at the end of the quarter was $450 thousand, and a $1.5 million investment was announced shortly after [12]. Future Outlook - The company is optimistic about the growth of its product pipeline and expects clinical acceptance of new products to take 9-12 months [7]. - Ongoing and planned clinical studies for both VIVO and LockeT are set to further demonstrate their efficacy and improve workflows [5].

Q1 2025 Revenue of $28.0 millionQ1 2025 Net loss of $2.0 millionQ1 2025 Adjusted EBITDA loss of $2.5 million All figures are reported in United States dollars ($) unless otherwise indicated LAS VEGAS, May 14, 2025 (GLOBE NEWSWIRE) -- Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced its financial results for the three-month period ended March 31, 2025. Planet 13’s financial statements are prepared i ...

Core Insights - Marpai, Inc. is experiencing a turnaround with a focus on reducing operating expenses and improving profitability, aiming for positive cash flow by the end of 2025 [2][8] Financial Performance - For Q1 2025, net revenues were approximately $5.4 million, a decrease of $2.0 million or 27% year-over-year compared to Q1 2024 [8] - Operating expenses were $7.7 million, down $3.8 million or 33% year-over-year [8] - The operating loss was $2.3 million, which is $1.8 million or 45% lower year-over-year [8] - The net loss was $3.1 million, a reduction of $1.3 million or 29% year-over-year [8] - Basic and diluted earnings per share improved to ($0.21), an increase of $0.25 per share year-over-year [8] Cash Position - At the end of Q1 2025, the company had $0.7 million in unrestricted cash, a decrease of $0.1 million from the previous year [8] - Total cash, cash equivalents, and restricted cash at the end of the period amounted to $11.5 million, down from $13.6 million year-over-year [12] Strategic Initiatives - The company is launching a Healthcare Management tool in collaboration with Empara, LLC and making advancements with MarpaiRx [2] - The onboarding of a new Chief Operating Officer, Dallas Scrip, is part of the company's strategic initiatives [2] Market Position - Marpai operates in the $22 billion Third-Party Administration (TPA) sector, serving self-funded employer health plans that represent over $1 trillion in annual claims [4]

Core Viewpoint - BioRestorative Therapies, Inc. reported its first quarter 2025 financial results and highlighted significant advancements in its clinical programs, particularly in stem cell-based therapies for disc/spine and metabolic disorders [1][2]. Corporate Highlights - The company has successfully achieved key clinical program milestones since the beginning of 2025 and is focused on executing its growth strategy while managing resources effectively [2]. - BioRestorative confirmed no material exposure to newly imposed U.S. tariffs, attributing this to its 'made-in-America' production strategy [5]. - The CEO participated in an interview at the Benzinga All-Access Show, discussing the company's progress [5]. - The company presented positive preliminary data from its ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease (cLDD) at the Orthopaedic Research Society Annual Meeting [5]. - The FDA granted Fast Track designation to the BRTX-100 program for cLDD, which may lead to Priority Review and Accelerated Biologics License Application approval [5]. - The FDA also cleared the Investigational New Drug application for BRTX-100 for chronic cervical discogenic pain, expanding the clinical pipeline [5]. Clinical Programs - The BRTX-100 program aims to treat chronic lower back pain from degenerative disc disease and has shown promising preliminary efficacy trends [5][11]. - The company is developing the ThermoStem metabolic disease platform, targeting obesity and metabolic disorders using brown adipose-derived stem cells [12]. - BioRestorative operates a commercial BioCosmeceutical platform, focusing on cell-based secretome products for cosmetic applications [13]. Financial Results - First quarter 2025 revenues were $25,000, down from $35,000 in the same period last year [7]. - The company reported a loss from operations of $4.8 million for the first quarter of 2025, compared to a loss of $4.1 million in the same period of 2024 [7]. - The net loss for the first quarter of 2025 was $5.3 million, or $0.64 per share, compared to a net loss of $2.2 million, or $0.33 per share, in the first quarter of 2024 [8]. - Cash used in operating activities was $2.8 million in Q1 2025, compared to $2.3 million in Q1 2024 [8]. - The company ended the first quarter of 2025 with $9.1 million in cash and cash equivalents, with no outstanding debt [9].